Cargando…
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients
Vaccination against SARS-CoV-2 using mRNA-based vaccines has been highly recommended for fragile subjects, including myelofibrosis patients (MF). Available data on the immune responsiveness of MF patients to mRNA SARS-CoV-2 vaccination, and the impact of the therapy with the JAK inhibitor ruxolitini...
Autores principales: | Fiorino, Fabio, Ciabattini, Annalisa, Sicuranza, Anna, Pastore, Gabiria, Santoni, Adele, Simoncelli, Martina, Polvere, Jacopo, Galimberti, Sara, Baratè, Claudia, Sammartano, Vincenzo, Montagnani, Francesca, Bocchia, Monica, Medaglini, Donata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556722/ https://www.ncbi.nlm.nih.gov/pubmed/36248803 http://dx.doi.org/10.3389/fimmu.2022.1017863 |
Ejemplares similares
-
The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose
por: Fiorino, Fabio, et al.
Publicado: (2021) -
A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses
por: Pettini, Elena, et al.
Publicado: (2022) -
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine
por: Ciabattini, Annalisa, et al.
Publicado: (2023) -
Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?
por: Pettini, Elena, et al.
Publicado: (2021) -
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
por: Ciabattini, Annalisa, et al.
Publicado: (2021)